{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,25]],"date-time":"2026-08-25T02:02:40Z","timestamp":1787623360345,"version":"build-2736575974"},"reference-count":61,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2023,7,18]],"date-time":"2023-07-18T00:00:00Z","timestamp":1689638400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100002341","name":"Academy of Finland","doi-asserted-by":"publisher","award":["308375"],"award-info":[{"award-number":["308375"]}],"id":[{"id":"10.13039\/501100002341","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:sec><jats:title>Introduction<\/jats:title><jats:p>Bisphosphonates (BPs) are bone-protecting osteoclast inhibitors, typically used in the treatment of osteoporosis and skeletal complications of malignancies. When given in the adjuvant setting, these drugs may also prevent relapses and prolong overall survival in early breast cancer (EBC), specifically among postmenopausal patients. Because of these findings, adjuvant nitrogen-containing BPs (N-BPs), such as zoledronate (ZOL), are now the standard of care for high-risk EBC patients, but there are no benefit-associated biomarkers, and the efficacy remains low. BPs have been demonstrated to possess anti-tumor activities, but the mechanisms by which they provide the beneficial effects in EBC are not known. <\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>We used stably transfected 4T1 breast cancer cells together with suppression of CD73 (sh-CD73) or control cells (sh-NT). We compared ZOL effects on tumor growth and infiltrating lymphocytes (TILs) into tumors and lung metastases using two mouse models. B cell depletion was performed using anti-CD20 antibody.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>Sh-CD73 4T1 cells were significantly more sensitive to the growth inhibitory effects of n-BPs <jats:italic>in vitro<\/jats:italic>. However, while ZOL-induced growth inhibition was similar between the tumor groups <jats:italic>in vivo<\/jats:italic>, ZOL enhanced B and T lymphocyte infiltration into the orthotopic tumors with down-regulated CD73. A similar trend was detected in lung metastases. ZOL-induced tumor growth inhibition was found to be augmented with B cell depletion in sh-NT tumors, but not in sh-CD73 tumors. As an internal control, ZOL effects on bone were similar in mice bearing both tumor groups.<\/jats:p><\/jats:sec><jats:sec><jats:title>Discussion<\/jats:title><jats:p>Taken together, these results indicate that ZOL modifies TILs in breast cancer, both in primary tumors and metastases. Our results further demonstrate that B cells may counteract the growth inhibitory effects of ZOL. However, all ZOL-induced TIL effects may be influenced by immunomodulatory characteristics of the tumor. <\/jats:p><\/jats:sec>","DOI":"10.3389\/fimmu.2023.1179022","type":"journal-article","created":{"date-parts":[[2023,7,18]],"date-time":"2023-07-18T08:04:42Z","timestamp":1689667482000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":7,"title":["CD73 regulates zoledronate-induced lymphocyte infiltration in triple-negative breast cancer tumors and lung metastases"],"prefix":"10.3389","volume":"14","author":[{"given":"Nataliia","family":"Petruk","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arafat","family":"Siddiqui","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sina","family":"Tadayon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jorma","family":"M\u00e4\u00e4tt\u00e4","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pieta K.","family":"Mattila","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arja","family":"Jukkola","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jouko","family":"Sandholm","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katri S.","family":"Selander","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2023,7,18]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1007\/s11657-018-0439-3","article-title":"Real-world effectiveness of osteoporosis therapies for fracture reduction in post-menopausal women","volume":"13","author":"Yusuf","year":"2018","journal-title":"Arch Osteoporos"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1080\/01635581.2016.1158293","article-title":"Zoledronate and molecular iodine cause synergistic cell death in triple negative breast cancer through endoplasmic reticulum stress","volume":"68","author":"Tripathi","year":"2016","journal-title":"Nutr Cancer"},{"key":"B3","doi-asserted-by":"crossref","first-page":"20155","DOI":"10.1038\/s41598-019-56622-5","article-title":"Dichotomic effects of clinically used drugs on tumor growth, bone remodeling and pain management","volume":"9","author":"Andr\u00e9 Barri\u00e8re","year":"2019","journal-title":"Sci Rep"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.18632\/oncotarget.13570","article-title":"Toll-like receptor 9 expression is associated with breast cancer sensitivity to the growth inhibitory effects of bisphosphonates in vitro and in vivo","volume":"7","author":"Sandholm","year":"2016","journal-title":"Oncotarget"},{"key":"B5","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s13046-019-1109-z","article-title":"Zoledronic acid inhibits the growth of cancer stem cell derived from cervical cancer cell by attenuating their stemness phenotype and inducing apoptosis and cell cycle arrest through the Erk1\/2 and akt pathways","volume":"38","author":"Wang","year":"2019","journal-title":"J Exp Clin Cancer Res"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1016\/j.canlet.2009.06.003","article-title":"Zoledronic acid induces apoptosis and changes the TRAIL\/OPG ratio in breast cancer cells","volume":"287","author":"Rachner","year":"2010","journal-title":"Cancer Lett"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1007\/s13277-015-3192-x","article-title":"Zoledronate can promote apoptosis and inhibit the proliferation of colorectal cancer cells","volume":"36","author":"Gao","year":"2015","journal-title":"Tumor Biol"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2018.02.004","article-title":"Adjuvant zoledronic acid reduces fractures in breast cancer patients; an AZURE (BIG 01\/04) study","volume":"94","author":"Wilson","year":"2018","journal-title":"Eur J Cancer"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1016\/j.clon.2012.10.010","article-title":"Bisphosphonates in the adjuvant treatment of breast cancer","volume":"25","author":"Winter","year":"2013","journal-title":"Clin Oncol"},{"key":"B10","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1007\/s11864-018-0535-z","article-title":"Adjuvant bisphosphonate therapy in postmenopausal breast cancer","volume":"19","author":"Strobl","year":"2018","journal-title":"Curr Treat Options Oncol"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1002\/1529-0131(200109)44:9<2201::AID-ART374>3.0.CO;2-E","article-title":"The molecular mechanism of action of the antiresorptive and antiinflammatory drug clodronate: evidence for the formation in vivo of a metabolite that inhibits bone resorption and causes osteoclast and macrophage apoptosis","volume":"44","author":"Frith","year":"2001","journal-title":"Arthritis Rheumatol"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/djv360","article-title":"CAPG and gipc1: breast cancer biomarkers for bone metastasis development and treatment","volume":"108","author":"Westbrook","year":"2016","journal-title":"J Natl Cancer Inst"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1007\/s00428-019-02722-6","article-title":"CD73 expression and pathologic response to neoadjuvant chemotherapy in triple negative breast cancer","volume":"476","author":"Cerbelli","year":"2020","journal-title":"Virchows Arch"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1111\/jcmm.15500","article-title":"CD73 acts as a prognostic biomarker and promotes progression and immune escape in pancreatic cancer","volume":"24","author":"Chen","year":"2020","journal-title":"J Cell Mol Med"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2021.08.006","article-title":"Impact of intratumoural CD73 expression on prognosis and therapeutic response in patients with gastric cancer","volume":"157","author":"He","year":"2021","journal-title":"Eur J Cancer"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2020-001467","article-title":"Prognostic significance and immune correlates of CD73 expression in renal cell carcinoma","volume":"8","author":"Tripathi","year":"2020","journal-title":"J Immunother Cancer"},{"key":"B17","doi-asserted-by":"publisher","first-page":"3982","DOI":"10.3390\/cancers13163982","article-title":"Cd73 promotes tumor progression in patients with esophageal squamous cell carcinoma","volume":"13","author":"Chen","year":"2021","journal-title":"Cancers (Basel)"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1007\/s00262-021-02893-9","article-title":"CD73 expression defines immune, molecular, and clinicopathological subgroups of lung adenocarcinoma","volume":"70","author":"Rocha","year":"2021","journal-title":"Cancer Immunol Immunother"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.0908801107","article-title":"Anti-CD73 antibody therapy inhibits breast tumor growth and metastasis","volume":"107","author":"Stagg","year":"2010","journal-title":"Proc Natl Acad Sci"},{"key":"B20","doi-asserted-by":"publisher","first-page":"6035","DOI":"10.1038\/s41598-021-85379-z","article-title":"CD73 facilitates EMT progression and promotes lung metastases in triple-negative breast cancer","volume":"11","author":"Petruk","year":"2021","journal-title":"Sci Rep"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdx730\/4627685","article-title":"Clinical significance of CD73 in triple-negative breast cancer: multiplex analysis of a phase III clinical trial","volume":"29","author":"Buisseret","year":"2018","journal-title":"Ann Oncol"},{"key":"B22","doi-asserted-by":"publisher","first-page":"889","DOI":"10.1186\/s12885-021-08601-1","article-title":"Neo-CheckRay: radiation therapy and adenosine pathway blockade to increase benefit of immuno-chemotherapy in early stage luminal B breast cancer, a randomized phase II trial","volume":"21","author":"De Caluw\u00e9","year":"2021","journal-title":"BMC Cancer"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2003-05-1655","article-title":"Induction of \u03b3\u03b4 T-lymphocyte effector functions by bisphosphonate zoledronic acid in cancer patients in vivo [3]","volume":"102","author":"Dieli","year":"2003","journal-title":"Blood"},{"key":"B24","doi-asserted-by":"publisher","first-page":"176","DOI":"10.1186\/s12885-019-5379-9","article-title":"Zoledronic acid blocks the interaction between breast cancer cells and regulatory T-cells","volume":"19","author":"Liu","year":"2019","journal-title":"BMC Cancer"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.982821","article-title":"SNAI1-dependent upregulation of CD73 increases extracellular adenosine release to mediate immune suppression in TNBC","volume":"13","author":"Hasmim","year":"2022","journal-title":"Front Immunol"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2019.00925","article-title":"Targeting adenosine in cancer immunotherapy to enhance T-cell function","volume":"10","author":"Vigano","year":"2019","journal-title":"Front Immunol"},{"key":"B27","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1186\/s40425-016-0165-6","article-title":"Clinical significance of tumor-infiltrating lymphocytes in breast cancer","volume":"4","author":"Stanton","year":"2016","journal-title":"J ImmunoTher Cancer"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1007\/s10549-011-1590-3","article-title":"Estrogen receptor-\u03b1 and sex steroid hormones regulate toll-like receptor-9 expression and invasive function in human breast cancer cells","volume":"132","author":"Sandholm","year":"2012","journal-title":"Breast Cancer Res Treat"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.14806\/ej.17.1.200","article-title":"Cutadapt removes adapter sequences from high-throughput sequencing reads","volume":"17","author":"Martin","year":"2011","journal-title":"EMBnet.journal"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1038\/nmeth.3317","article-title":"HISAT: a fast spliced aligner with low memory requirements","volume":"12","author":"Kim","year":"2015","journal-title":"Nat Methods"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1038\/nbt.3122","article-title":"StringTie enables improved reconstruction of a transcriptome from RNA-seq reads","volume":"33","author":"Pertea","year":"2015","journal-title":"Nat Biotechnol"},{"key":"B32","doi-asserted-by":"publisher","first-page":"550","DOI":"10.1186\/s13059-014-0550-8","article-title":"Moderated estimation of fold change and dispersion for RNA-seq data with DESeq2","volume":"15","author":"Love","year":"2014","journal-title":"Genome Biol"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1093\/bioinformatics\/btp616","article-title":"edgeR: a bioconductor package for differential expression analysis of digital gene expression data","volume":"26","author":"Robinson","year":"2009","journal-title":"Bioinformatics"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1096\/fj.00-0268com","article-title":"Extracellular ATP formation on vascular endothelial cells is mediated by ecto-nucleotide kinase activities via phosphotransfer reactions","volume":"15","author":"Yegutkin","year":"2001","journal-title":"FASEB J"},{"key":"B35","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41598-018-26198-7","article-title":"Stretching reduces tumor growth in a mouse breast cancer model","volume":"8","author":"Berrueta","year":"2018","journal-title":"Sci Rep"},{"key":"B36","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41598-017-17204-5","article-title":"QuPath: open source software for digital pathology image analysis","volume":"7","author":"Bankhead","year":"2017","journal-title":"Sci Rep"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.1172\/JCI3523","article-title":"TGF-\u03b2 signaling blockade inhibits PTHrP secretion by breast cancer cells and bone metastases development","volume":"103","author":"Yin","year":"1999","journal-title":"J Clin Invest"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pbio.3000410","article-title":"The arrive guidelines 2.0: updated guidelines for reporting animal research","volume":"18","author":"du Sert","year":"2020","journal-title":"PloS Biol"},{"key":"B39","doi-asserted-by":"publisher","first-page":"534","DOI":"10.1186\/s12859-018-2486-6","article-title":"iDEP: an integrated web application for differential expression and pathway analysis of RNA-seq data","volume":"19","author":"Ge","year":"2018","journal-title":"BMC Bioinf"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-019-1730-1","article-title":"A view on drug resistance in cancer","volume":"575","author":"Vasan","year":"2019","journal-title":"Nature"},{"key":"B41","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-12-3497","article-title":"Margin-infiltrating CD20+ b cells display an atypical memory phenotype and correlate with favorable prognosis in hepatocellular carcinoma","volume":"19","author":"Shi","year":"2013","journal-title":"Clin Cancer Res"},{"key":"B42","doi-asserted-by":"publisher","DOI":"10.3892\/ol.2017.5810","article-title":"B cells inhibit the antitumor immunity against an established murine fibrosarcoma","volume":"13","author":"Maglioco","year":"2017","journal-title":"Oncol Lett"},{"key":"B43","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-16-0040","article-title":"CTLA-4 limits anti-CD20-mediated tumor regression","volume":"23","author":"Ren","year":"2017","journal-title":"Clin Cancer Res"},{"key":"B44","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-16-0547","article-title":"Oral bisphosphonates and improved survival of breast cancer","volume":"23","author":"Rennert","year":"2017","journal-title":"Clin Cancer Res"},{"key":"B45","doi-asserted-by":"publisher","DOI":"10.1038\/s41401-021-00840-z","article-title":"Therapeutic efficacy and mechanism of CD73-TGF\u03b2 dual-blockade in a mouse model of triple-negative breast cancer","volume":"43","author":"Xing","year":"2022","journal-title":"Acta Pharmacol Sin"},{"key":"B46","doi-asserted-by":"publisher","DOI":"10.1016\/j.jconrel.2021.07.021","article-title":"Cancer-cell-biomimetic upconversion nanoparticles combining chemo-photodynamic therapy and CD73 blockade for metastatic triple-negative breast cancer","volume":"337","author":"Jin","year":"2021","journal-title":"J Control Release"},{"key":"B47","doi-asserted-by":"publisher","DOI":"10.1007\/s00784-015-1584-3","article-title":"Altered macrophagic THP-1 cell phagocytosis and migration in bisphosphonate-related osteonecrosis of the jaw (BRONJ)","volume":"20","author":"Hoefert","year":"2016","journal-title":"Clin Oral Investig"},{"key":"B48","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1186\/s41232-018-0074-9","article-title":"Zoledronic acid exacerbates inflammation through M1 macrophage polarization","volume":"38","author":"Kaneko","year":"2018","journal-title":"Inflammation Regen"},{"key":"B49","doi-asserted-by":"publisher","DOI":"10.1096\/fj.201801791RR","article-title":"Zoledronic acid promotes TLR-4-mediated M1 macrophage polarization in bisphosphonate-related osteonecrosis of the jaw","volume":"33","author":"Zhu","year":"2019","journal-title":"FASEB J"},{"key":"B50","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.1200744","article-title":"Inhibition of CD73 improves B cell-mediated anti-tumor immunity in a mouse model of melanoma","volume":"189","author":"Forte","year":"2012","journal-title":"J Immunol"},{"key":"B51","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.1600089","article-title":"Features of human CD3+CD20+ T cells","volume":"197","author":"Schuh","year":"2016","journal-title":"J Immunol"},{"key":"B52","doi-asserted-by":"publisher","DOI":"10.1093\/brain\/awy301","article-title":"Proinflammatory CD20+ T cells in the pathogenesis of multiple sclerosis","volume":"142","author":"Von Essen","year":"2019","journal-title":"Brain"},{"key":"B53","doi-asserted-by":"publisher","DOI":"10.1016\/j.celrep.2013.09.004","article-title":"Bisphosphonates target B cells to enhance humoral immune responses","volume":"5","author":"Tonti","year":"2013","journal-title":"Cell Rep"},{"key":"B54","doi-asserted-by":"publisher","first-page":"108952","DOI":"10.1016\/j.intimp.2022.108952","article-title":"Pamidronate, a promising repositioning drug to treat leishmaniasis, displays antileishmanial and immunomodulatory potential","volume":"110","author":"Ribeiro","year":"2022","journal-title":"Int Immunopharmacol"},{"key":"B55","doi-asserted-by":"publisher","DOI":"10.1016\/j.clinthera.2016.03.026","article-title":"Current challenges in cancer treatment","volume":"38","author":"Zugazagoitia","year":"2016","journal-title":"Clin Ther"},{"key":"B56","doi-asserted-by":"publisher","DOI":"10.1007\/s000110050332","article-title":"Estrogen-mediated immunosuppression in autoimmune diseases","volume":"47","author":"Jansson","year":"","journal-title":"Inflammation Res"},{"key":"B57","doi-asserted-by":"publisher","DOI":"10.7150\/thno.58390","article-title":"Turning cold tumors into hot tumors by improving T-cell infiltration","volume":"11","author":"Liu","year":"2021","journal-title":"Theranostics"},{"key":"B58","doi-asserted-by":"publisher","DOI":"10.1038\/d41586-019-03943-0","article-title":"B cells to the forefront of immunotherapy","volume":"577","author":"Bruno","year":"2020","journal-title":"Nature"},{"key":"B59","doi-asserted-by":"publisher","DOI":"10.1038\/nrc.2017.121","article-title":"Targeting B cell receptor signalling in cancer: preclinical and clinical advances","volume":"18","author":"Burger","year":"2018","journal-title":"Nat Rev Cancer"},{"key":"B60","doi-asserted-by":"publisher","DOI":"10.1016\/j.ctrv.2018.12.001","article-title":"B cell and B cell-related pathways for novel cancer treatments","volume":"73","author":"Tokunaga","year":"2019","journal-title":"Cancer Treat Rev"},{"key":"B61","doi-asserted-by":"publisher","first-page":"286","DOI":"10.1186\/s12885-021-08009-x","article-title":"Tumor-infiltrating B cells and T cells correlate with postoperative prognosis in triple-negative carcinoma of the breast","volume":"21","author":"Kuroda","year":"2021","journal-title":"BMC Cancer"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2023.1179022\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,7,18]],"date-time":"2023-07-18T08:04:46Z","timestamp":1689667486000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2023.1179022\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,7,18]]},"references-count":61,"alternative-id":["10.3389\/fimmu.2023.1179022"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2023.1179022","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,7,18]]},"article-number":"1179022"}}